18F-FDG PET/CT in the detection of asymptomatic malignant melanoma recurrence

Ismaheel Lawal, Thabo Lengana, Kehinde Ololade

  • 1Mike M. Sathekge, MD, PhD, Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Private Bag X169, Pretoria 0001, South Africa, Phone: +27 123541794, Fax: +27 123541219,

Abstract

Insights

Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) effectively detects asymptomatic malignant melanoma recurrence. Lymph nodes are the most common recurrence site, with sex, nodal metastasis, and tumor features predicting recurrence.

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Diagnostic Imaging

Background:

  • Malignant melanoma recurrence can be asymptomatic.
  • Early detection of recurrence is crucial for patient outcomes.
  • Identifying predictors of recurrence aids in risk stratification.

Purpose of the Study:

  • To assess the diagnostic accuracy of FDG PET/CT for detecting asymptomatic malignant melanoma recurrence.
  • To determine the common patterns of recurrence.
  • To identify factors that predict disease recurrence.

Main Methods:

  • 144 patients with resected malignant melanoma and no clinical signs of recurrence underwent FDG PET/CT.
  • Diagnostic accuracy (sensitivity, specificity, accuracy) of FDG PET/CT was calculated.
  • Patterns of recurrence and predictive factors were analyzed.

Main Results:

  • Asymptomatic recurrence was detected in 25.7% of patients, with a median time to recurrence of 20 months.
  • Lymph nodes were the most frequent site of recurrence.
  • Sex, tumor depth, histology type, and nodal metastasis were significant predictors of recurrence. FDG PET/CT demonstrated high diagnostic accuracy (94.5% sensitivity, 87.6% specificity, 89.6% accuracy).

Conclusions:

  • FDG PET/CT is a valuable tool for the early detection of asymptomatic malignant melanoma recurrence.
  • Lymph node metastasis is the most common pattern of recurrence.
  • Patient sex, nodal metastasis status, and pathological tumor characteristics are key predictors of recurrence.